Treating complex movement disorders in children with cerebral palsy

Ulster Medical Journal

Volumn 78, Issue 3, 2009, Pages 157-163

  Lundy, Claire ^a   Lumsden, Daniel ^a   Fairhurst, Charlie ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN A; DIAZEPAM; TETRABENAZINE; TRIHEXYPHENIDYL;

ABSENCE OF SIDE EFFECTS; AGITATION; BASAL GANGLION; BEHAVIOR DISORDER; BRAIN DEPTH STIMULATION; CEREBRAL PALSY; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRY EYE; DYSTONIA; ELECTROMYOGRAM; FECES INCONTINENCE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEMATOMA; HUMAN; HYPERTHERMIA; MOTOR DYSFUNCTION; MUSCLE TONE; MUSCLE WEAKNESS; MYDRIASIS; PALLIDOTOMY; PARKINSONISM; PATIENT EDUCATION; PATIENT SELECTION; PRURITUS; REVIEW; SEIZURE; SIDE EFFECT; SPASTICITY; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

BACLOFEN; BOTULINUM TOXINS; CEREBRAL PALSY; DEEP BRAIN STIMULATION; HUMANS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SPINAL; MOVEMENT DISORDERS; MUSCLE RELAXANTS, CENTRAL; RECEPTORS, GABA;

EID: 73349084271     PISSN: 00416193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE). Dev Med Child Neurol 2000;42(12):816-24.
2. Beckung E, White-Koning M, Marcelli M, McManus V, Michelsen S, Parkes J, et al. Health status of children with cerebral palsy living in Europe: a multi-centre study. Child Care Health Dev 2008;34(6):806-14.
3. Gilmartin R, Bruce D, Storrs BB, Abbott R, Krach L, Ward J, et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol 2000;15(2):71-7.
4. Albright AL. Neurosurgical treatment of spasticity and other pediatric movement disorders. J Child Neurol 2003;18(Suppl 1): S67-S78.
5. Verrotti A, Greco R, Spalice A, Chiarelli F, Iannetti P. Pharmacotherapy of spasticity in children with cerebral palsy. Pediatr Neurol 2006;34(1):1-6.
6. Zhuang P, Li Y, Hallett M. Neuronal activity in the basal ganglia and thalamus in patients with dystonia. Clin Neurophysiol 2004;115(11):2542-57.
7. Coffey JR, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993;78(2):226-32.
8. Levin AB, Sperling KB. Complications associated with infusion pumps implanted for spasticity. Stereotact Funct Neurosurg 1995;65(1-4): 147-51.
9. Woon K, Tsegaye M, Vloeberghs MH. The role of intrathecal baclofen in the management of primary and secondary dystonia in children. Br J Neurosurg 2007;21(4):355-8.
10. Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes Committee Review Panel. Dev Med Child Neurol 2000;42(9):634-45.
11. Bensmail D, Quera Salva MA, Roche N, Benyahia S, Bohic M, Denys P, et al. Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology 2006;67(8):1432-6.
12. Baker R, Jasinski M, Maciag-Tymecka I, Michalowska-Mrozek J, Bonikowski M, Carr L, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002;44(10):666-75.
13. Carr LJ, Cosgrove AP, Gringras P, Neville BG. Position paper on the use of botulinum toxin in cerebral palsy. UK Botulinum Toxin and Cerebral Palsy Working Party. Arch Dis Child 1998;79(3):271-3.
14. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994;36(5):386-96.
15. Lundy CT, Doherty GM, Fairhurst CB. Botulinum toxin type A injections can be an effective treatment for pain in children with hip spasms and cerebral palsy. Dev Med Child Neurol Epub 2009. Apr 21.
16. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006;13(Suppl 4):1-9.
17. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006;312(5773):592-6.
18. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004;20(7):981-90.
19. Association of Paediatric Chartered Physiotherapists. Evidence based guidance for physiotherapists: the use of Botulinum Toxin in children with neurological conditions. Huntingdon: APCP; 2008.
20. Himmelmann K, Hagberg G, Wiklund LM, Eek MN, Uvebrant P. Dyskinetic cerebral palsy: a population-based study of children born between 1991 and 1998. Dev Med Child Neurol 2007;49(4):246-51.
21. de Carvalho Aguiar PM, Ozelius LJ. Classification and genetics of dystonia. Lancet Neurol 2002;1(5):316-25.
22. Han F, Racacho L, Lang AE, Bulman DE, Grimes DA. Refinement of the DYT15 locus in myoclonus dystonia. Mov Disord 2007;22(6):888-92.
23. Grotzsch H, Pizzolato GP, Ghika J, Schorderet D, Vingerhoets FJ, Landis T, et al. Neuropathology of a case of dopa-responsive dystonia associated with a new genetic locus, DYT14. Neurology 2002;58(12):1839-42.
24. Klein C, Breakefield XO, Ozelius LJ. Genetics of primary dystonia. Semin Neurol 1999;19(3):271-80.
25. Marsden CD, Obeso JA, Zarranz JJ, Lang AE. The anatomical basis of symptomatic hemidystonia. Brain 1985;108(2):463-83.
26. Pettigrew LC, Jankovic J. Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry 1985;48(7):650-7.
27. Quartarone A, Rizzo V, Morgante F. Clinical features of dystonia: a pathophysiological revisitation. Curr Opin Neurol 2008;21(4):484- 90.
28. Sanghera MK, Grossman RG, Kalhorn CG, Hamilton WJ, Ondo WG, Jankovic J. Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery 2003;52(6):1358-70.
29. Vitek JL, Chockkan V, Zhang JY, Kaneoke Y, Evatt M, DeLong MR, et al. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol 1999;46(1):22-35.
30. Chen CC, Kuhn AA, Trottenberg T, Kupsch A, Schneider GH, Brown P. Neuronal activity in globus pallidus interna can be synchronized to local field potential activity over 3-12 Hz in patients with dystonia. Exp Neurol 2006;202(2):480-6.
31. Chen CC, Kuhn AA, Hoffmann KT, Kupsch A, Schneider GH, Trottenberg T, et al. Oscillatory pallidal local field potential activity correlates with involuntary EMG in dystonia. Neurology 2006;66(3):418-20.
32. Sharott A, Grosse P, Kuhn AA, Salih F, Engel AK, Kupsch A, et al. Is the synchronization between pallidal and muscle activity in primary dystonia due to peripheral afferance or a motor drive? Brain 2008;131(2): 473-84.
33. Fahn S. High-dosage anticholinergic therapy in dystonia. Adv Neurol 1983;37:177-88.
34. Hoon AH, Jr., Freese PO, Reinhardt EM, Wilson MA, Lawrie WT, Jr., Harryman SE, et al. Age-dependent effects of trihexyphenidyl in extrapyramidal cerebral palsy. Pediatr Neurol 2001;25(1):55-8.
35. Sanger TD, Bastian A, Brunstrom J, Damiano D, Delgado M, Dure L, et al. Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy. J Child Neurol 2007;22(5):530-7.
36. Jain S, Greene PE, Frucht SJ. Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Mov Disord 2006;21(11):1966-72.
37. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48(2):358-62.
38. Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004;27(5):230-3.
39. Krause M, Fogel W, Kloss M, Rasche D, Volkmann J, Tronnier V. Pallidal stimulation for dystonia. Neurosurgery 2004;55(6):1361-8.
40. Vidailhet M, Vercueil L, Houeto JL, Krystkowiak P, Benabid AL, Cornu P, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005;352(5):459-67.
41. Vidailhet M, Vercueil L, Houeto JL, Krystkowiak P, Lagrange C, Yelnik J, et al. Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol 2007;6(3):223-9.
42. Coubes P, Cif L, El FH, Hemm S, Vayssiere N, Serrat S, et al. Electrical stimulation of the globus pallidus internus in patients with primary generalized dystonia: long-term results. J Neurosurg 2004;101(2): 189-94.
43. Bittar RG, Yianni J, Wang S, Liu X, Nandi D, Joint C, et al. Deep brain stimulation for generalised dystonia and spasmodic torticollis. J Clin Neurosci 2005;12(1):12-6.
44. Castelnau P, Cif L, Valente EM, Vayssiere N, Hemm S, Gannau A, et al. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Ann Neurol 2005;57(5):738-41.
45. Dostrovsky JO, Lozano AM. Mechanisms of deep brain stimulation. Mov Disord 2002;17(Suppl 3):S63-S68.
46. Kuncel AM, Grill WM. Selection of stimulus parameters for deep brain stimulation. Clin Neurophysiol 2004;115(11):2431-41.
47. Vitek JL. Mechanisms of deep brain stimulation: excitation or inhibition. Mov Disord 2002;17(Suppl 3):S69-S72.
48. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985;35(1):73-7.
49. Eltahawy HA, Saint-Cyr J, Giladi N, Lang AE, Lozano AM. Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation. Neurosurgery 2004;54(3):613-9.